Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 22, Issue 2, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-06
DOI
10.1007/s11912-020-0881-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
- (2019) Annika Scheffold et al. BLOOD
- Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
- (2019) Eugen Tausch et al. HAEMATOLOGICA
- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
- (2019) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
- (2019) Romain Guièze et al. CANCER CELL
- Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
- (2018) Steven Coutre et al. BLOOD
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).
- (2018) Von Tresckow Julia et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
- (2018) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
- (2018) Bola S. Hanna et al. LEUKEMIA
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2018) G. Fraser et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Venetoclax for the treatment of patients with chronic lymphocytic leukemia
- (2017) Jennifer Crombie et al. Future Oncology
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents
- (2017) Bruce D. Cheson et al. ONCOLOGIST
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- The Phospholipase Cγ2Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein
- (2016) Claudia Walliser et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial
- (2016) Tadeusz Robak et al. LEUKEMIA & LYMPHOMA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
- (2015) C. J. Gibson et al. CLINICAL CANCER RESEARCH
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
- (2015) C. Moreno et al. HAEMATOLOGICA
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
- (2015) Peter Hillmen et al. LANCET
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
- (2015) K Balakrishnan et al. LEUKEMIA
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
- (2015) Thomas J. Kipps et al. LEUKEMIA & LYMPHOMA
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
- (2015) C. Moreno et al. HAEMATOLOGICA
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy
- (2014) J. A. Woyach et al. BLOOD
- Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
- (2014) P. Dreger et al. BLOOD
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Uncovering the DNA methylome in chronic lymphocytic leukemia
- (2013) Nicola Cahill et al. Epigenetics
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- The Tumor Lysis Syndrome
- (2011) Scott C. Howard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic lymphocytic leukemia: planning for an aging population
- (2010) John G Gribben Expert Review of Anticancer Therapy
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
- (2009) Jorge Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started